|
Severe hereditary factor VIII deficiency disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hemostatic Effect of Tranexamic Acid Combined With Factor VIII Concentrate in Prophylactic Setting in Severe Hemophilia A: a preclinical study.
|
31782901 |
2020 |
|
Severe hereditary factor VIII deficiency disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial.
|
31513978 |
2019 |
|
Severe hereditary factor VIII deficiency disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated whether blocking B-cell receptor signaling upon inhibition of Bruton tyrosine kinase prevents anti-factor VIII immune responses in a mouse model of severe hemophilia A.
|
30545924 |
2019 |
|
Severe hereditary factor VIII deficiency disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes.
|
31115111 |
2019 |
|
Severe hereditary factor VIII deficiency disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study.
|
31015264 |
2019 |
|
Severe hereditary factor VIII deficiency disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evaluation of EC50 of factor VIII as predictor of prophylaxis efficacy in patients with severe haemophilia A.
|
30529268 |
2019 |
|
Severe hereditary factor VIII deficiency disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies.
|
31066174 |
2019 |
|
Severe hereditary factor VIII deficiency disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dose tailoring of human cell line-derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A.
|
30633808 |
2019 |
|
Severe hereditary factor VIII deficiency disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Previously treated males aged 12-65 years with severe haemophilia A who completed the PROTECT VIII main study were eligible for the open-label extension.
|
31621991 |
2019 |
|
Severe hereditary factor VIII deficiency disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
: Prophylaxis with factor VIII concentrates is the cornerstone of treatment for severe hemophilia A.
|
31157677 |
2019 |
|
Severe hereditary factor VIII deficiency disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Inhibitor formation is a life-long risk for patients with non-severe hemophilia A treated with therapeutic factor VIII, but remains difficult to predict.
|
30266735 |
2019 |
|
Severe hereditary factor VIII deficiency disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A.
|
31194850 |
2019 |
|
Severe hereditary factor VIII deficiency disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Continuous infusions of B domain-truncated recombinant factor VIII, turoctocog alfa, for orthopedic surgery in severe hemophilia A: first case report.
|
29383626 |
2018 |
|
Severe hereditary factor VIII deficiency disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study.
|
29848837 |
2018 |
|
Severe hereditary factor VIII deficiency disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
|
29139314 |
2018 |
|
Severe hereditary factor VIII deficiency disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein.
|
29082639 |
2018 |
|
Severe hereditary factor VIII deficiency disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
To characterize the pharmacokinetic (PK) profile of BAY 94-9027 from phase 1, phase 2/3 (PROTECT VIII) and phase 3 (PROTECT VIII Kids) clinical trials in adults, adolescents and children with severe haemophilia A METHODS: Patients with severe haemophilia A (FVIII <1%) with >50 FVIII exposure days (EDs) and no history of inhibitors were included in the phase 1 (18-65 years, ≥150 EDs), PROTECT VIII (12-65 years, ≥150 EDs) and PROTECT VIII Kids (<12 years, >50 EDs) trials.
|
29963724 |
2018 |
|
Severe hereditary factor VIII deficiency disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States.
|
29681200 |
2018 |
|
Severe hereditary factor VIII deficiency disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Beginning in October 2012, 200 patients with moderate or severe hemophilia A or B (factor VIII or IX level ≤ 5%), aged 54 to 73 years, were enrolled at 19 US hemophilia treatment centers.
|
29895623 |
2018 |
|
Severe hereditary factor VIII deficiency disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The effect of unmeasurable endogenous plasma factor activity levels on factor VIII dosing in patients with severe hemophilia A.
|
30118868 |
2018 |
|
Severe hereditary factor VIII deficiency disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
He was subsequently diagnosed with severe haemophilia A due to intron 22 inversion in the factor VIII gene, with factor VIII level <0.01 IU/mL.
|
30413439 |
2018 |
|
Severe hereditary factor VIII deficiency disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interestingly, this peptide was found to have a higher predicted affinity for HLA-DQ than for HLA-DR. Taken together, our data suggest that HLA-DQ participates in the presentation of factor VIII peptides, thereby contributing to the development of inhibitory antibodies in a proportion of patients with severe hemophilia A.
|
29025906 |
2018 |
|
Severe hereditary factor VIII deficiency disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Oxidation of factor VIII increases its immunogenicity in mice with severe hemophilia A.
|
29395036 |
2018 |
|
Severe hereditary factor VIII deficiency disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We selected boys with severe hemophilia A (factor VIII <1 IU/dL) first treated with one of the three factor VIII products studied.
|
29025913 |
2018 |
|
Severe hereditary factor VIII deficiency disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis.
|
29436077 |
2018 |